-
Swedish company BioLamina to enable next-generation cell therapies for serious chronic diseases with €20 million EIB commitment
Sundbyberg, April 16, 2026 Swedish company BioLamina to enable next-generation cell therapies for serious chronic diseases with €20 million EIB co […]
-
Biolaminin 521 supports animal origin-free hESC-RPE differentiation and retinal rescue
This study demonstrates that combining a fully defined, animal origin-free culture medium with a physiologically relevant extracellular matrix is ke […]
-
Biolaminin®-functionalized Biosilk scaffolds model dopaminergic neurogenesis in ventral midbrain organoids
By using a Biolaminin 111–functionalized Biosilk scaffold, the system produces organoids with stable cell-type composition, reliable dopaminergic […]
-
Biosilk/Biolaminin® system supports long-term, uniform 3D neural tissue development
Biosilk and Biolaminin 521 enabled centimeter-scale, channel-permeated 3D cultures that differentiated uniformly into neuroectoderm followed by furt […]
-
Biosilk recreates native tissue properties in 3D culture
Biosilk brings 3D culture closer to native tissue biology by providing an ECM-like microfiber architecture that supports firm cell attachment, sprea […]
-
Laminin-augmented extracellular matrix improves human brain reconstruction
Brain organoids are valuable for modeling human brain development and disease but often lack the complex extracellular matrix (ECM) cues needed for […]
-
Cell X Technologies and BioLamina enter a collaboration to advance standardization in iPSC-based therapeutics
Sundbyberg, September 29, 2025 Cell X Technologies and BioLamina enter a collaboration to advance standardization in iPSC-based therapeutics BioLami […]
-
Pluristyx and BioLamina Announce Strategic Partnership to Accelerate Development of Stem Cell-Based Therapies
Sundbyberg, September 4, 2025 Pluristyx and BioLamina Announce Strategic Partnership to Accelerate Development of Stem Cell-Based Therapies Pluristy […]
-
BioLamina appoints Brian Hawkins, PhD as new Chief Technology Officer (CTO).
Stockholm, March 3, 2025 BioLamina appoints Brian Hawkins, PhD, as new Chief Technology Officer (CTO). BioLamina AB, appoints Brian Hawkins as Chief […]
-
Find our Biolaminin® 521 LN in the new PluriKit™ by PluriStyx
Find our Biolaminin® 521 LN in the new PluriKit™ by PluriStyx We are proud to have been chosen by PluriStyx as their […]